Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic versus no antibiotic treatment for low-risk catheter-related coagulase-negative staphylococcal bacteremia
2017-003612-39Phase 4Terminated
- Sponsor
- Fundació Parc Taulí
- Start
- Apr 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dalbavancin, vancomycin, linezolid and daptomycin in catheter-associated bloodstream infection (CRBSI) and Staphylococcal bacteremia (2 arms), sponsored by Fundació Parc Taulí. Primary endpoint: Composite efficacy and safety endpoint. Started Apr 2018; status: terminated.
02
Drugs
dalbavancinvancomycinlinezoliddaptomycin
03
Conditions
catheter-associated bloodstream infection (CRBSI)Staphylococcal bacteremia
Beyond the preview
Go deeper on 2017-003612-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003612-39.